Drug Profile
Research programme: sulfonylurea receptor subtype agonists - Soleno Therapeutics
Latest Information Update: 10 Jul 2017
Price :
$50
*
At a glance
- Originator Essentialis
- Class
- Mechanism of Action Sulfonylurea receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lipid metabolism disorders; Obesity; Polycystic ovary syndrome; Type 1 diabetes mellitus
Most Recent Events
- 08 Mar 2017 Essentialis has merged with and became a subsidiary of Capnia
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lipid-metabolism-disorders in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (PO)